tirzepatide effect on insulin resistance for diabetes: track to SURPASS current therapy Novel Dual Incretin Receptor Agonists

Thielke et al

Blood samples were collected at week 4 and week 6

For CPT 0891T, using the available claims data from CY 2024, our analysis found the geometric mean cost was approximately $1,692, the median cost was approximately $1,009, and the arithmetic mean cost was approximately $2,010

If a program includes medication as part of care, access is determined only after provider review, and medications are sourced from a licensed 503B pharmacy as part of the overall program

Choose semaglutide if: Cost is the primary barrier, you have cardiovascular disease and need the SELECT trial CV evidence behind your treatment, or you respond well to GLP-1 therapy alone